Even, C <br/><br/>
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.  [electronic resource] 

 -  Investigational new drugs  04 2020 
 - 402-409 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-019-00739-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Benzazepines--adverse effects<br/>Carcinoma, Adenoid Cystic--drug therapy<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Progression-Free Survival<br/>Receptor, Notch1--antagonists & inhibitors<br/>Tumor Burden--drug effects